Long-Term Outcomes of Elagolix in Women With Endometriosis

Imagem de Miniatura
Arquivos
art_SURREY_LongTerm_Outcomes_of_Elagolix_in_Women_With_Endometriosis_2018.PDF (5 MB)
Citações na Scopus
91
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
SURREY, Eric
TAYLOR, Hugh S.
GIUDICE, Linda
LESSEY, Bruce A.
ARCHER, David F.
DIAMOND, Michael P.
JOHNSON, Neil P.
WATTS, Nelson B.
GALLAGHER, J. Chris
Citação
OBSTETRICS AND GYNECOLOGY, v.132, n.1, p.147-160, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were extension studies that evaluated an additional 6 months of treatment after two 6-month, double-blind, placebo-controlled phase 3 trials (12 continuous treatment months) with two elagolix doses (150 mg once daily and 200 mg twice daily). Coprimary efficacy endpoints were the proportion of responders (clinically meaningful pain reduction and stable or decreased rescue analgesic use) based on average monthly dysmenorrhea and nonmenstrual pelvic pain scores. Safety assessments included adverse events, clinical laboratory tests, and endometrial and bone mineral density assessments. The power of Elaris EM-III and -IV was based on the comparison to placebo in Elaris EM-I and -II with an expected 25% dropout rate. RESULTS: Between December 28, 2012, and October 31, 2014 (Elaris EM-III), and between May 27, 2014, and January 6, 2016 (Elaris EM-IV), 569 participants were enrolled. After 12 months of treatment, Elaris EM-III responder rates for dysmenorrhea were 52.1% at 150 mg once daily (Elaris EM-IV=50.8%) and 78.1% at 200 mg twice daily (Elaris EM-IV=75.9%). Elaris EM-III nonmenstrual pelvic pain responder rates were 67.8% at 150 mg once daily (Elaris EM-IV=66.4%) and 69.1% at 200 mg twice daily (Elaris EM-IV=67.2%). After 12 months of treatment, Elaris EM-III dyspareunia responder rates were 45.2% at 150 mg once daily (Elaris EM-IV=45.9%) and 60.0% at 200 mg twice daily (Elaris EM-IV=58.1%). Hot flush was the most common adverse event. Decreases from baseline in bone mineral density and increases from baseline in lipids were observed after 12 months of treatment. There were no adverse endometrial findings. CONCLUSION: Long-term elagolix treatment provided sustained reductions in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia. The safety was consistent with reduced estrogen levels and no new safety concerns were associated with long-term elagolix use.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/29984
Referências
  1. BARBIERI RL, 1992, AM J OBSTET GYNECOL, V166, P740, DOI 10.1016/0002-9378(92)91706-G
  2. Brown J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009590.pub2
  3. Brown J, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008475.pub2
  4. Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690
  5. Burney RO, 2007, ENDOCRINOLOGY, V148, P3814, DOI 10.1210/en.2006-1692
  6. Burney RO, 2012, FERTIL STERIL, V98, P511, DOI 10.1016/j.fertnstert.2012.06.029
  7. Carr B, 2014, REPROD SCI, V21, P1341, DOI 10.1177/1933719114549848
  8. Diamond MP, 2014, REPROD SCI, V21, P363, DOI 10.1177/1933719113497292
  9. Dragoman MV, 2016, CONTRACEPTION, V94, P202, DOI 10.1016/j.contraception.2016.02.003
  10. Dunselman GAJ, 2014, HUM REPROD, V29, P400, DOI 10.1093/humrep/det457
  11. Fuldeore MJ, 2017, GYNECOL OBSTET INVES, V82, P453, DOI 10.1159/000452660
  12. Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274
  13. Hornstein MD, 1998, OBSTET GYNECOL, V91, P16, DOI 10.1016/S0029-7844(97)00620-0
  14. Johnson NP, 2017, HUM REPROD, V32, P315, DOI 10.1093/humrep/dew293
  15. Marjoribanks J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001751.pub3
  16. Ng J, 2017, J CLIN ENDOCR METAB, V102, P1683, DOI 10.1210/jc.2016-3845
  17. Petta CA, 2005, HUM REPROD, V20, P1993, DOI 10.1093/humrep/deh869
  18. Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073
  19. Simpson Paul D, 2015, Post Reprod Health, V21, P16, DOI 10.1177/2053369114568440
  20. Soliman AM, 2017, J PSYCHOSOM OBST GYN, V38, P238, DOI 10.1080/0167482X.2017.1289512
  21. Soliman AM, 2016, HUM REPROD, V31, P712, DOI 10.1093/humrep/dev335
  22. Taylor HS, 2017, NEW ENGL J MED, V377, P28, DOI 10.1056/NEJMoa1700089
  23. The International Society For Clinical Densitometry, 2015, 2015 ISCD OFF POS AD

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - LIM/58